Marei Maram, El-Nikhely Nefertiti, Sheta Eman, Ragab Hanan, Wahid Ahmed, Saeed Hesham, Rostom Sherif A F
Department of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, 21521, Egypt.
Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, 21521, Egypt.
Drug Des Devel Ther. 2025 May 15;19:3857-3882. doi: 10.2147/DDDT.S512058. eCollection 2025.
Liver fibrosis is a life-threatening disease that greatly impacts the morbidity and mortality of hepatic patients worldwide, resulting mainly as a consequence of hepatitis C, alcoholic and non-alcoholic fatty liver. COX-1 and COX-2 isozymes catalyze the synthesis of prostaglandins (PGs) and thromboxanes (TXs) from arachidonic acid causing inflammation. Owing to the scarcity of approved fibrolytic drugs available for human use, celecoxib (a selective COX-2 inhibitor) has been repurposed as a potential antifibrotic and fibrolytic agent in some chronic liver fibrosis models.
The present study aims to discover a non-invasive treatment for liver fibrosis through investigating the possible ability of three celecoxib-related bipyrazole compounds to reverse chemically induced liver fibrosis in rats using CCl. This fibrolytic effect was verified by histopathological, immunohistochemical, biochemical and biomolecular assays. In addition, in silico computer-aided evaluation of the compounds' binding mode to certain molecular targets was performed, and the in silico physicochemical properties, drug likeness and pharmacokinetic parameters were predicted using web-based applications.
The analogs could serve as novel therapeutic candidates for the mitigation of liver fibrosis that deserves further derivatizations and investigations. In particular, the fluorinated analog proved to be the most active member in this study when compared to celecoxib due to its distinguished histopathological and immunohistochemical investigation results, beside its antioxidant potential, as well as its reliable effects against some biomarkers, namely, MMP-9, TGF-β1, TIMP-1, IL-6 and TNF-α.
Based on the obtained results, the fluorinated analog could serve as a novel therapeutic candidate for the amelioration of liver fibrosis that deserves further derivatizations and investigations.
肝纤维化是一种危及生命的疾病,对全球肝病患者的发病率和死亡率有重大影响,主要由丙型肝炎、酒精性和非酒精性脂肪肝引起。COX-1和COX-2同工酶催化花生四烯酸合成前列腺素(PGs)和血栓素(TXs),从而引发炎症。由于可供人类使用的获批纤溶药物稀缺,塞来昔布(一种选择性COX-2抑制剂)在一些慢性肝纤维化模型中已被重新用作潜在的抗纤维化和纤溶药物。
本研究旨在通过研究三种与塞来昔布相关的双吡唑化合物使用CCl诱导大鼠化学性肝纤维化的可能逆转能力,发现一种非侵入性的肝纤维化治疗方法。通过组织病理学、免疫组织化学、生化和生物分子检测验证了这种纤溶作用。此外,对化合物与某些分子靶点的结合模式进行了计算机辅助评估,并使用基于网络的应用程序预测了其计算机物理化学性质、药物相似性和药代动力学参数。
这些类似物可作为减轻肝纤维化的新型治疗候选物,值得进一步衍生化和研究。特别是,与塞来昔布相比,氟化类似物在本研究中被证明是最具活性的成员,这得益于其卓越的组织病理学和免疫组织化学研究结果、抗氧化潜力以及对一些生物标志物(即MMP-9、TGF-β1、TIMP-1、IL-6和TNF-α)的可靠作用。
基于所得结果,氟化类似物可作为改善肝纤维化的新型治疗候选物,值得进一步衍生化和研究。